



## Clinical trial results:

### A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)

#### Summary

EudraCT number	2016-004678-16
Trial protocol	ES
Global end of trial date	13 July 2020

#### Results information

Result version number	v1 (current)
This version publication date	29 July 2021
First version publication date	29 July 2021

#### Trial information

##### Trial identification

Sponsor protocol code	INCB 24360-207 / ECHO-207
-----------------------	---------------------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03085914
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Incyte
Sponsor organisation address	1801 Augustine Cutoff drive, Wilmington, United States, 19803
Public contact	Study Director, Incyte Corporation, 3022744765 18554633463, skanthala@incyte.com
Scientific contact	Study Director, Incyte Corporation, 3022744765 18554633463, skanthala@incyte.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	13 July 2020
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	13 July 2020
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

This was an open-label, nonrandomized, Phase 1/2 study designed to determine the safety, tolerability, and efficacy of epacadostat when given in combination with pembrolizumab and 7 different chemotherapy regimens described as Treatment Groups A through G. Phase 1 consisted of a 3 + 3 + 3 design intended to determine the MTD or PAD of epacadostat when given in combination with pembrolizumab and chemotherapy; efficacy was also explored.

Phase 2 was designed to enroll efficacy expansion cohorts to further evaluate the safety, tolerability, and efficacy of epacadostat at the MTD or PAD (as selected in Phase 1) when given in combination with pembrolizumab and chemotherapy. No participants were enrolled in any Phase 2 efficacy expansion cohort.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were also followed during the conduct of the trial.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	02 May 2017
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	United States: 70
Worldwide total number of subjects	70
EEA total number of subjects	0

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0

Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	48
From 65 to 84 years	22
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

The study was conducted at 9 US sites. Phase 1 and 2 each consisted of Treatment Groups A-G, and every patient in the same group received the same dose of epacadostat, pembrolizumab and respective chemotherapy regimens. Data analysis and summarization were performed by treatment group, by combining data of the same group in Phase 1 and 2.

### Pre-assignment

Screening details:

A total of 70 participants were enrolled in the study. Study enrollment was permanently discontinued on 25 Oct 2018 as a strategic decision.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Group A: Epa + Pembrolizumab +mFOLFOX6

Arm description:

Epacadostat (Epa, 100 mg ) oral twice-daily (BID) continuous daily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg)administered intravenously (IV) in combination with mFOLFOX6 (oxaliplatin IV + leucovorin IV + 5-fluorouracil (5-FU) IV.

Arm type	Experimental
Investigational medicinal product name	Epacadostat
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

epacadostat was dosed at 100 mg twice a day, if this was not tolerated within a treatment group, epacadostat 50 mg BID was evaluated.

<b>Arm title</b>	Group B: Epa + Pembrolizumab + nab-Paclitaxel and Gemcitabine
------------------	---

Arm description:

Epa (100 mg) oral BID continuous daily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) IV in combination with nab-paclitaxel IV and gemcitabine IV.

Arm type	Experimental
Investigational medicinal product name	Epacadostat
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

epacadostat was dosed at 100 mg twice a day, if this was not tolerated within a treatment group, epacadostat 50 mg BID was evaluated.

<b>Arm title</b>	Group C: Epa + Pembrolizumab + Paclitaxel and Carboplatin
------------------	---

Arm description:

Epa (100 mg) oral BID continuous daily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) in combination with paclitaxel IV and carboplatin IV.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Epacadostat
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

epacadostat was dosed at 100 mg twice a day, if this was not tolerated within a treatment group, epacadostat 50 mg BID was evaluated.

<b>Arm title</b>	Group D: Epa + Pembrolizumab + Pemetrexed and Platinum Agent
------------------	--

Arm description:

Epa (100 mg) oral BID continuous daily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) IV in combination with pemetrexed IV and Investigator's choice of platinum agent: carboplatin IV or cisplatin IV.

Arm type	Experimental
Investigational medicinal product name	Epacadostat
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

epacadostat was dosed at 100 mg twice a day, if this was not tolerated within a treatment group, epacadostat 50 mg BID was evaluated.

<b>Arm title</b>	Group E: Epa + Pembrolizumab + Cyclophosphamide
------------------	---

Arm description:

Epa (100 mg) oral BID continuous daily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) IV in combination with cyclophosphamide PO.

Arm type	Experimental
Investigational medicinal product name	Epacadostat
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

epacadostat was dosed at 100 mg twice a day, if this was not tolerated within a treatment group, epacadostat 50 mg BID was evaluated.

<b>Arm title</b>	Group F: Epa + Pembrolizumab + Gemcitabine and Platinum Agent
------------------	---

Arm description:

Epa (100 mg) oral BID continuous daily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) IV in combination with gemcitabine IV and Investigator's choice of platinum agent: carboplatin IV or cisplatin IV.

Arm type	Experimental
Investigational medicinal product name	Epacostat
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

epacadostat was dosed at 100 mg twice a day, if this was not tolerated within a treatment group, epacadostat 50 mg BID was evaluated.

<b>Arm title</b>	Group G: Epa + Pembrolizumab + 5-FU and Platinum Agent
------------------	--

Arm description:

Epa (100 mg) oral BID continuous daily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) IV in combination with 5-FU IV and Investigator's choice of platinum agent:

carboplatin IV or cisplatin IV.

Arm type	Experimental
Investigational medicinal product name	Epacadostat
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

epacadostat was dosed at 100 mg twice a day, if this was not tolerated within a treatment group, epacadostat 50 mg BID was evaluated.

Number of subjects in period 1	Group A: Epa + Pembrolizumab + mFOLFOX6	Group B: Epa + Pembrolizumab + nab-Paclitaxel and Gemcitabine	Group C: Epa + Pembrolizumab + Paclitaxel and Carboplatin
Started	9	9	11
Completed	0	0	0
Not completed	9	9	11
Withdrawal by Participant	1	1	2
Study terminated by the sponsor.	-	-	-
Death	6	6	4
Progressive Disease	-	-	2
Reason not specified	2	2	2
Lost to follow-up	-	-	1

Number of subjects in period 1	Group D: Epa + Pembrolizumab + Pemetrexed and Platinum Agent	Group E: Epa + Pembrolizumab + Cyclophosphamide	Group F: Epa + Pembrolizumab + Gemcitabine and Platinum Agent
Started	9	13	8
Completed	0	0	0
Not completed	9	13	8
Withdrawal by Participant	2	2	-
Study terminated by the sponsor.	1	2	1
Death	1	5	2
Progressive Disease	2	1	1
Reason not specified	3	3	3
Lost to follow-up	-	-	1

Number of subjects in period 1	Group G: Epa + Pembrolizumab + 5-FU and Platinum Agent
Started	11
Completed	0
Not completed	11
Withdrawal by Participant	1

Study terminated by the sponsor.	-
Death	2
Progressive Disease	1
Reason not specified	6
Lost to follow-up	1

## Baseline characteristics

Reporting groups	
Reporting group title	Group A: Epa + Pembrolizumab + mFOLFOX6
Reporting group description: Epacadostat (Epa, 100 mg ) oral twice-daily (BID) continuous daily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) administered intravenously (IV) in combination with mFOLFOX6 (oxaliplatin IV + leucovorin IV + 5-fluorouracil (5-FU) IV.	
Reporting group title	Group B: Epa + Pembrolizumab + nab-Paclitaxel and Gemcitabine
Reporting group description: Epa (100 mg) oral BID continuous daily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) IV in combination with nab-paclitaxel IV and gemcitabine IV.	
Reporting group title	Group C: Epa + Pembrolizumab + Paclitaxel and Carboplatin
Reporting group description: Epa (100 mg) oral BID continuous daily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) in combination with paclitaxel IV and carboplatin IV.	
Reporting group title	Group D: Epa + Pembrolizumab + Pemetrexed and Platinum Agent
Reporting group description: Epa (100 mg) oral BID continuous daily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) IV in combination with pemetrexed IV and Investigator's choice of platinum agent: carboplatin IV or cisplatin IV.	
Reporting group title	Group E: Epa + Pembrolizumab + Cyclophosphamide
Reporting group description: Epa (100 mg) oral BID continuous daily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) IV in combination with cyclophosphamide PO.	
Reporting group title	Group F: Epa + Pembrolizumab + Gemcitabine and Platinum Agent
Reporting group description: Epa (100 mg) oral BID continuous daily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) IV in combination with gemcitabine IV and Investigator's choice of platinum agent: carboplatin IV or cisplatin IV.	
Reporting group title	Group G: Epa + Pembrolizumab + 5-FU and Platinum Agent
Reporting group description: Epa (100 mg) oral BID continuous daily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) IV in combination with 5-FU IV and Investigator's choice of platinum agent: carboplatin IV or cisplatin IV.	

Reporting group values	Group A: Epa + Pembrolizumab + mFOLFOX6	Group B: Epa + Pembrolizumab + nab-Paclitaxel and Gemcitabine	Group C: Epa + Pembrolizumab + Paclitaxel and Carboplatin
Number of subjects	9	9	11
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	8	8	6



From 65-84 years	1	1	5
85 years and over	0	0	0

Age Continuous Units: years arithmetic mean standard deviation	55.8 ± 8.03	46.0 ± 14.98	63.7 ± 12.11
Sex: Female, Male Units:			
Female	3	4	6
Male	6	5	5
Race/Ethnicity, Customized Units: Subjects			
White/Caucasian	7	7	9
Black/African-American	2	1	0
Asian	0	0	1
Native Hawaiian/Pacific Islander	0	0	0
Other	0	1	1
Race/Ethnicity, Customized Units: Subjects			
Hispanic or Latino	0	0	0
Not Hispanic or Latino	9	9	11
Not Reported	0	0	0
Unknown	0	0	0

<b>Reporting group values</b>	Group D: Epa + Pembrolizumab + Pemetrexed and Platinum Agent	Group E: Epa + Pembrolizumab + Cyclophosphamide	Group F: Epa + Pembrolizumab + Gemcitabine and Platinum Agent
Number of subjects	9	13	8
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	6	8	5
From 65-84 years	3	5	3
85 years and over	0	0	0
Age Continuous Units: years arithmetic mean standard deviation	58.2 ± 12.96	62.0 ± 10.21	60.3 ± 12.01
Sex: Female, Male Units:			
Female	4	10	5
Male	5	3	3

Race/Ethnicity, Customized Units: Subjects			
White/Caucasian	8	10	6
Black/African-American	0	1	0
Asian	0	0	2
Native Hawaiian/Pacific Islander	1	0	0
Other	0	2	0
Race/Ethnicity, Customized Units: Subjects			
Hispanic or Latino	0	0	0
Not Hispanic or Latino	7	13	8
Not Reported	1	0	0
Unknown	1	0	0

<b>Reporting group values</b>	Group G: Epa + Pembrolizumab + 5- FU and Platinum Agent	Total	
Number of subjects	11	70	
Age categorical Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	7	48	
From 65-84 years	4	22	
85 years and over	0	0	
Age Continuous Units: years			
arithmetic mean	59.4		
standard deviation	± 12.24	-	
Sex: Female, Male Units:			
Female	4	36	
Male	7	34	
Race/Ethnicity, Customized Units: Subjects			
White/Caucasian	8	55	
Black/African-American	2	6	
Asian	0	3	
Native Hawaiian/Pacific Islander	0	1	
Other	1	5	
Race/Ethnicity, Customized Units: Subjects			
Hispanic or Latino	1	1	
Not Hispanic or Latino	10	67	
Not Reported	0	1	
Unknown	0	1	



## End points

### End points reporting groups

Reporting group title	Group A: Epa + Pembrolizumab + mFOLFOX6
Reporting group description: Epacadostat (Epa, 100 mg ) oral twice-daily (BID) continuous daily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) administered intravenously (IV) in combination with mFOLFOX6 (oxaliplatin IV + leucovorin IV + 5-fluorouracil (5-FU) IV.	
Reporting group title	Group B: Epa + Pembrolizumab + nab-Paclitaxel and Gemcitabine
Reporting group description: Epa (100 mg) oral BID continuous daily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) IV in combination with nab-paclitaxel IV and gemcitabine IV.	
Reporting group title	Group C: Epa + Pembrolizumab + Paclitaxel and Carboplatin
Reporting group description: Epa (100 mg) oral BID continuous daily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) in combination with paclitaxel IV and carboplatin IV.	
Reporting group title	Group D: Epa + Pembrolizumab + Pemetrexed and Platinum Agent
Reporting group description: Epa (100 mg) oral BID continuous daily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) IV in combination with pemetrexed IV and Investigator's choice of platinum agent: carboplatin IV or cisplatin IV.	
Reporting group title	Group E: Epa + Pembrolizumab + Cyclophosphamide
Reporting group description: Epa (100 mg) oral BID continuous daily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) IV in combination with cyclophosphamide PO.	
Reporting group title	Group F: Epa + Pembrolizumab + Gemcitabine and Platinum Agent
Reporting group description: Epa (100 mg) oral BID continuous daily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) IV in combination with gemcitabine IV and Investigator's choice of platinum agent: carboplatin IV or cisplatin IV.	
Reporting group title	Group G: Epa + Pembrolizumab + 5-FU and Platinum Agent
Reporting group description: Epa (100 mg) oral BID continuous daily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) IV in combination with 5-FU IV and Investigator's choice of platinum agent: carboplatin IV or cisplatin IV.	

### Primary: Phases 1 and 2 : Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

End point title	Phases 1 and 2 : Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs <sup>[1]</sup>
End point description: A TEAE is any AE either reported for the first time or worsening of a pre-existing event after first dose of epacadostat, pembrolizumab, or chemotherapy. Serious adverse event is defined as an event that meets 1 of the following criteria: is fatal or life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability, incapacity, or a substantial disruption of a person's ability to conduct normal life functions, constitutes a congenital anomaly or birth defect, is a medically important event that may jeopardize the participant or may require medical or surgical intervention to prevent 1 of the outcomes listed above.	
End point type	Primary
End point timeframe: Up to 21 months	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses for this end point

End point values	Group A: Epa + Pembrolizumab + mFOLFOX6	Group B: Epa + Pembrolizumab + nab-Paclitaxel and Gemcitabine	Group C: Epa + Pembrolizumab + Paclitaxel and Carboplatin	Group D: Epa + Pembrolizumab + Pemetrexed and Platinum Agent
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	9	11	9
Units: participants				
TEAE	9	9	11	9
Serious TEAE	5	5	5	3

End point values	Group E: Epa + Pembrolizumab + Cyclophosphamide	Group F: Epa + Pembrolizumab + Gemcitabine and Platinum Agent	Group G: Epa + Pembrolizumab + 5-FU and Platinum Agent	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	13	8	11	
Units: participants				
TEAE	13	8	11	
Serious TEAE	6	4	6	

## Statistical analyses

No statistical analyses for this end point

## Primary: Phases 1 and 2: Number of participants with Dose Limiting Toxicities (DLTs)

End point title	Phases 1 and 2: Number of participants with Dose Limiting Toxicities (DLTs) <sup>[2]</sup>
-----------------	--

End point description:

A DLT was defined as the occurrence of any of the protocol-specified toxicities occurring up to and including Day 28 for the cohorts where mFOLFOX6 and nab-paclitaxel/gemcitabine are administered and Day 21 for all other chemotherapy regimens in Phase 1, except those with a clear alternative explanation (eg, disease progression) or transient ( $\leq 72$  hours) abnormal laboratory values without associated clinically significant signs or symptoms based on investigator determination.

End point type	Primary
----------------	---------

End point timeframe:

28 days

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses for this end point

End point values	Group A: Epa + Pembrolizumab + mFOLFOX6	Group B: Epa + Pembrolizumab + nab-Paclitaxel and Gemcitabine	Group C: Epa + Pembrolizumab + Paclitaxel and Carboplatin	Group D: Epa + Pembrolizumab + Pemetrexed and Platinum Agent
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	9	11	9
Units: participants	0	2	0	0

End point values	Group E: Epa + Pembrolizumab + Cyclophosphamide	Group F: Epa + Pembrolizumab + Gemcitabine and Platinum Agent	Group G: Epa + Pembrolizumab + 5-FU and Platinum Agent	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	13	8	11	
Units: participants	0	0	3	

### Statistical analyses

No statistical analyses for this end point

### Primary: Phases 1 and 2 : Objective Response Rate (ORR)

End point title	Phases 1 and 2 : Objective Response Rate (ORR) <sup>[3]</sup>
-----------------	---

End point description:

ORR was defined as the percentage of participants having a complete response (CR) or partial response (PR) as determined by investigator assessment of radiographic disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

End point type	Primary
----------------	---------

End point timeframe:

Up to Week 18

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses for this end point

End point values	Group A: Epa + Pembrolizumab + mFOLFOX6	Group B: Epa + Pembrolizumab + nab-Paclitaxel and Gemcitabine	Group C: Epa + Pembrolizumab + Paclitaxel and Carboplatin	Group D: Epa + Pembrolizumab + Pemetrexed and Platinum Agent
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	9	11	9
Units: Participants				
Complete Response	0	0	1	0
Partial Response	5	5	2	3

<b>End point values</b>	Group E: Epa + Pembrolizumab + Cyclophosphamide	Group F: Epa + Pembrolizumab + Gemcitabine and Platinum Agent	Group G: Epa + Pembrolizumab + 5-FU and Platinum Agent	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	13	8	11	
Units: Participants				
Complete Response	0	0	0	
Partial Response	2	3	1	

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Up to 21 months

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	22
--------------------	----

### Reporting groups

Reporting group title	Group A: Epa + Pembrolizumab +mFOLFOX6
-----------------------	--

Reporting group description:

Epacadostat (Epa, 100 mg ) oral twice-daily (BID) continuous daily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) administered intravenously (IV) in combination with mFOLFOX6 (oxaliplatin IV + leucovorin IV + 5-fluorouracil (5-FU) IV.

Reporting group title	Group B: Epa + Pembrolizumab + nab-Paclitaxel and Gemcitabine
-----------------------	---

Reporting group description:

Epa (100 mg) oral BID continuous daily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) IV in combination with nab-paclitaxel IV and gemcitabine IV.

Reporting group title	Group C: Epa + Pembrolizumab + Paclitaxel and Carboplatin
-----------------------	---

Reporting group description:

Epa (100 mg) oral BID continuous daily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) in combination with paclitaxel IV and carboplatin IV.

Reporting group title	Group D: Epa + Pembrolizumab + Pemetrexed and Platinum Agent
-----------------------	--

Reporting group description:

Epa (100 mg) oral BID continuous daily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) IV in combination with pemetrexed IV and Investigator's choice of platinum agent: carboplatin IV or cisplatin IV.

Reporting group title	Group E: Epa + Pembrolizumab + Cyclophosphamide
-----------------------	---

Reporting group description:

Epa (100 mg) oral BID continuous daily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) IV in combination with cyclophosphamide PO.

Reporting group title	Group F: Epa + Pembrolizumab + Gemcitabine and Platinum Agent
-----------------------	---

Reporting group description:

Epa (100 mg) oral BID continuous daily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) IV in combination with gemcitabine IV and Investigator's choice of platinum agent: carboplatin IV or cisplatin IV.

Reporting group title	Group G: Epa + Pembrolizumab + 5-FU and Platinum Agent
-----------------------	--

Reporting group description:

Epa (100 mg) oral BID continuous daily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) IV in combination with 5-FU IV and Investigator's choice of platinum agent: carboplatin IV or cisplatin IV.

Reporting group title	Total
-----------------------	-------

Reporting group description:

Total



<b>Serious adverse events</b>	<b>Group A: Epa + Pembrolizumab + mFOLFOX6</b>	<b>Group B: Epa + Pembrolizumab + nab-Paclitaxel and Gemcitabine</b>	<b>Group C: Epa + Pembrolizumab + Paclitaxel and Carboplatin</b>
Total subjects affected by serious adverse events			
subjects affected / exposed	5 / 9 (55.56%)	5 / 9 (55.56%)	5 / 11 (45.45%)
number of deaths (all causes)	6	6	4
number of deaths resulting from adverse events	2	3	3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cervix cancer metastatic			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Malignant neoplasm progression			
subjects affected / exposed	0 / 9 (0.00%)	2 / 9 (22.22%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 2	0 / 0
Tumour pain			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Hypotension			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Orthostatic hypotension			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Death			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 11 (9.09%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Disease progression			

subjects affected / exposed	2 / 9 (22.22%)	0 / 9 (0.00%)	3 / 11 (27.27%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 2
Pyrexia			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Vaginal haemorrhage			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 11 (9.09%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Ammonia increased			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutrophil count decreased			

subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 11 (9.09%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Platelet count decreased			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 11 (9.09%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
White blood cell count decreased			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 11 (9.09%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Lower limb fracture			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Palpitations			
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 11 (9.09%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal cord compression			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Syncope			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 11 (9.09%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile neutropenia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukopenia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphopenia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pure white cell aplasia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 11 (9.09%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			

Abdominal pain			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysphagia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophagitis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stomatitis			

subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	1 / 11 (9.09%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Bile duct obstruction			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	1 / 11 (9.09%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract obstruction			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Intervertebral disc degeneration			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Catheter site cellulitis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			

subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine infection			
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Failure to thrive			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperammonaemia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			

subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	2 / 11 (18.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Group D: Epa + Pembrolizumab + Pemetrexed and Platinum Agent	Group E: Epa + Pembrolizumab + Cyclophosphamide	Group F: Epa + Pembrolizumab + Gemcitabine and Platinum Agent
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 9 (33.33%)	6 / 13 (46.15%)	4 / 8 (50.00%)
number of deaths (all causes)	1	6	2
number of deaths resulting from adverse events	1	4	2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cervix cancer metastatic			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant neoplasm progression			
subjects affected / exposed	0 / 9 (0.00%)	2 / 13 (15.38%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 2	0 / 0
Tumour pain			
subjects affected / exposed	0 / 9 (0.00%)	1 / 13 (7.69%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Hypotension			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Orthostatic hypotension			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Death			



subjects affected / exposed	0 / 9 (0.00%)	1 / 13 (7.69%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Disease progression			
subjects affected / exposed	1 / 9 (11.11%)	1 / 13 (7.69%)	1 / 8 (12.50%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 1
Pyrexia			
subjects affected / exposed	0 / 9 (0.00%)	1 / 13 (7.69%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Vaginal haemorrhage			
subjects affected / exposed	0 / 9 (0.00%)	1 / 13 (7.69%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	1 / 9 (11.11%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	0 / 9 (0.00%)	1 / 13 (7.69%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Ammonia increased			

subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutrophil count decreased			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Platelet count decreased			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
White blood cell count decreased			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Lower limb fracture			
subjects affected / exposed	0 / 9 (0.00%)	1 / 13 (7.69%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Palpitations			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Spinal cord compression			
subjects affected / exposed	0 / 9 (0.00%)	1 / 13 (7.69%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 9 (0.00%)	1 / 13 (7.69%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile neutropenia			
subjects affected / exposed	1 / 9 (11.11%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukopenia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	1 / 8 (12.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphopenia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	1 / 8 (12.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	1 / 8 (12.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pure white cell aplasia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			

subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	1 / 8 (12.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 9 (0.00%)	1 / 13 (7.69%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysphagia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	1 / 8 (12.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 9 (0.00%)	1 / 13 (7.69%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophagitis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	0 / 9 (0.00%)	1 / 13 (7.69%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			

subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stomatitis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 9 (0.00%)	1 / 13 (7.69%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Bile duct obstruction			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	1 / 8 (12.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract obstruction			
subjects affected / exposed	1 / 9 (11.11%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Intervertebral disc degeneration			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Catheter site cellulitis			

subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	1 / 8 (12.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine infection			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 9 (0.00%)	1 / 13 (7.69%)	1 / 8 (12.50%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Urosepsis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Failure to thrive			
subjects affected / exposed	0 / 9 (0.00%)	1 / 13 (7.69%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperammonaemia			

subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	1 / 8 (12.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	1 / 8 (12.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Group G: Epa + Pembrolizumab + 5-FU and Platinum Agent	Total	
Total subjects affected by serious adverse events			
subjects affected / exposed	6 / 11 (54.55%)	34 / 70 (48.57%)	
number of deaths (all causes)	3	28	
number of deaths resulting from adverse events	2	17	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cervix cancer metastatic			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Malignant neoplasm progression			
subjects affected / exposed	0 / 11 (0.00%)	4 / 70 (5.71%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 4	
Tumour pain			
subjects affected / exposed	0 / 11 (0.00%)	2 / 70 (2.86%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Hypotension			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Orthostatic hypotension			

subjects affected / exposed	1 / 11 (9.09%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Death			
subjects affected / exposed	0 / 11 (0.00%)	2 / 70 (2.86%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 2	
Disease progression			
subjects affected / exposed	1 / 11 (9.09%)	9 / 70 (12.86%)	
occurrences causally related to treatment / all	0 / 1	0 / 9	
deaths causally related to treatment / all	0 / 1	0 / 8	
Pyrexia			
subjects affected / exposed	0 / 11 (0.00%)	2 / 70 (2.86%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Vaginal haemorrhage			
subjects affected / exposed	0 / 11 (0.00%)	2 / 70 (2.86%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea			
subjects affected / exposed	1 / 11 (9.09%)	2 / 70 (2.86%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			



subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Investigations</b>			
Ammonia increased			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutrophil count decreased			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Platelet count decreased			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
White blood cell count decreased			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Injury, poisoning and procedural complications</b>			
Lower limb fracture			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Cardiac disorders</b>			
Palpitations			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Nervous system disorders</b>			
Cerebrovascular accident			

subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Seizure			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal cord compression			
subjects affected / exposed	1 / 11 (9.09%)	2 / 70 (2.86%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Syncope			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 11 (0.00%)	2 / 70 (2.86%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Febrile neutropenia			
subjects affected / exposed	1 / 11 (9.09%)	2 / 70 (2.86%)	
occurrences causally related to treatment / all	0 / 1	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leukopenia			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphopenia			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutropenia			

subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pure white cell aplasia			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombocytopenia			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			
subjects affected / exposed	1 / 11 (9.09%)	2 / 70 (2.86%)	
occurrences causally related to treatment / all	0 / 1	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysphagia			
subjects affected / exposed	1 / 11 (9.09%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 11 (0.00%)	2 / 70 (2.86%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nausea			
subjects affected / exposed	1 / 11 (9.09%)	3 / 70 (4.29%)	
occurrences causally related to treatment / all	0 / 1	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophagitis			

subjects affected / exposed	1 / 11 (9.09%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal haemorrhage			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestinal obstruction			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stomatitis			
subjects affected / exposed	1 / 11 (9.09%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			
subjects affected / exposed	1 / 11 (9.09%)	4 / 70 (5.71%)	
occurrences causally related to treatment / all	0 / 1	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Bile duct obstruction			
subjects affected / exposed	0 / 11 (0.00%)	2 / 70 (2.86%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 11 (0.00%)	2 / 70 (2.86%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract obstruction			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue			

disorders			
Intervertebral disc degeneration			
subjects affected / exposed	1 / 11 (9.09%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Catheter site cellulitis			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza			
subjects affected / exposed	1 / 11 (9.09%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestine infection			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	0 / 11 (0.00%)	2 / 70 (2.86%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Urosepsis			
subjects affected / exposed	1 / 11 (9.09%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	1 / 1	1 / 1	
Metabolism and nutrition disorders			
Dehydration			

subjects affected / exposed	1 / 11 (9.09%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Failure to thrive			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperammonaemia			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyponatraemia			
subjects affected / exposed	0 / 11 (0.00%)	3 / 70 (4.29%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Group A: Epa + Pembrolizumab +mFOLFOX6	Group B: Epa + Pembrolizumab + nab-Paclitaxel and Gemcitabine	Group C: Epa + Pembrolizumab + Paclitaxel and Carboplatin
Total subjects affected by non-serious adverse events			
subjects affected / exposed	9 / 9 (100.00%)	8 / 9 (88.89%)	11 / 11 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Neoplasm progression			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Tumour flare			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Tumour haemorrhage			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Tumour inflammation			

subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0
Tumour pain subjects affected / exposed occurrences (all)	2 / 9 (22.22%) 2	2 / 9 (22.22%) 2	2 / 11 (18.18%) 3
Vascular disorders			
Capillary leak syndrome subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0
Flushing subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 2	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0
Hot flush subjects affected / exposed occurrences (all)	2 / 9 (22.22%) 2	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0
Hypertension subjects affected / exposed occurrences (all)	2 / 9 (22.22%) 2	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0
Hypotension subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 9 (11.11%) 1	0 / 11 (0.00%) 0
Thrombophlebitis superficial subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	1 / 11 (9.09%) 1
Thrombosis subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 9 (11.11%) 1	0 / 11 (0.00%) 0
Vascular pain subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	1 / 11 (9.09%) 1
General disorders and administration site conditions			
Asthenia subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	2 / 9 (22.22%) 2	1 / 11 (9.09%) 1
Axillary pain			

subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Catheter site pain			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Chest discomfort			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Chills			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	4 / 11 (36.36%)
occurrences (all)	0	0	4
Facial pain			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	7 / 9 (77.78%)	5 / 9 (55.56%)	6 / 11 (54.55%)
occurrences (all)	9	7	7
Gait disturbance			
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Generalised oedema			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Influenza like illness			
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	1 / 11 (9.09%)
occurrences (all)	1	0	1
Malaise			
subjects affected / exposed	1 / 9 (11.11%)	1 / 9 (11.11%)	0 / 11 (0.00%)
occurrences (all)	2	1	0
Non-cardiac chest pain			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Oedema			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Oedema peripheral			



subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	2 / 9 (22.22%) 2	0 / 11 (0.00%) 0
Pain subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 9 (11.11%) 1	1 / 11 (9.09%) 1
Pyrexia subjects affected / exposed occurrences (all)	2 / 9 (22.22%) 2	1 / 9 (11.11%) 1	0 / 11 (0.00%) 0
Temperature intolerance subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	1 / 11 (9.09%) 1
Immune system disorders Drug hypersensitivity subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0
Seasonal allergy subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 9 (11.11%) 1	0 / 11 (0.00%) 0
Reproductive system and breast disorders Testicular pain subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	1 / 11 (9.09%) 1
Vaginal haemorrhage subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0
Vaginal ulceration subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	1 / 11 (9.09%) 1
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	2 / 9 (22.22%) 2	2 / 9 (22.22%) 3	2 / 11 (18.18%) 2
Dysphonia subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0
Dyspnoea			

subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	2 / 11 (18.18%)
occurrences (all)	1	0	3
Dyspnoea exertional			
subjects affected / exposed	1 / 9 (11.11%)	1 / 9 (11.11%)	0 / 11 (0.00%)
occurrences (all)	1	1	0
Epistaxis			
subjects affected / exposed	0 / 9 (0.00%)	2 / 9 (22.22%)	1 / 11 (9.09%)
occurrences (all)	0	2	1
Haemoptysis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Hiccups			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Hypoxia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Nasal congestion			
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	1 / 11 (9.09%)
occurrences (all)	1	0	1
Nasal discomfort			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Oropharyngeal pain			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Painful respiration			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Pharyngeal inflammation			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Pneumonitis			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Pneumothorax			

subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Productive cough			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 11 (0.00%)
occurrences (all)	0	2	0
Pulmonary embolism			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	2 / 11 (18.18%)
occurrences (all)	0	0	2
Pulmonary fibrosis			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Rhinitis allergic			
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Wheezing			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Psychiatric disorders			
Anxiety			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Depression			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	2 / 11 (18.18%)
occurrences (all)	0	1	2
Insomnia			
subjects affected / exposed	2 / 9 (22.22%)	1 / 9 (11.11%)	2 / 11 (18.18%)
occurrences (all)	2	1	2
Irritability			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Mental status changes			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Product issues			
Stent malfunction			

subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Investigations			
Activated partial thromboplastin time prolonged			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Alanine aminotransferase increased			
subjects affected / exposed	3 / 9 (33.33%)	3 / 9 (33.33%)	3 / 11 (27.27%)
occurrences (all)	3	3	3
Amylase increased			
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Aspartate aminotransferase increased			
subjects affected / exposed	3 / 9 (33.33%)	3 / 9 (33.33%)	3 / 11 (27.27%)
occurrences (all)	3	4	4
Blood alkaline phosphatase increased			
subjects affected / exposed	2 / 9 (22.22%)	3 / 9 (33.33%)	3 / 11 (27.27%)
occurrences (all)	2	3	3
Blood bilirubin increased			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Blood creatinine increased			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	3 / 11 (27.27%)
occurrences (all)	0	0	5
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Blood pressure increased			
subjects affected / exposed	1 / 9 (11.11%)	1 / 9 (11.11%)	1 / 11 (9.09%)
occurrences (all)	1	1	1
Lipase increased			
subjects affected / exposed	2 / 9 (22.22%)	0 / 9 (0.00%)	2 / 11 (18.18%)
occurrences (all)	2	0	2
Lymphocyte count decreased			

subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	2 / 11 (18.18%) 2
Neutrophil count decreased subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 2	1 / 9 (11.11%) 1	3 / 11 (27.27%) 6
Neutrophil toxic granulation present subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	1 / 11 (9.09%) 1
Platelet count decreased subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	1 / 9 (11.11%) 1	2 / 11 (18.18%) 5
Shift to the left subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	1 / 11 (9.09%) 1
Transaminases increased subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0
Weight decreased subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	2 / 9 (22.22%) 2	1 / 11 (9.09%) 1
Weight increased subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	1 / 11 (9.09%) 1
White blood cell count decreased subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 2	1 / 9 (11.11%) 1	3 / 11 (27.27%) 7
Injury, poisoning and procedural complications			
Contusion subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0
Incision site pain subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	1 / 11 (9.09%) 1
Infusion related reaction			

subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Skin abrasion			
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Stoma site haemorrhage			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Stoma site inflammation			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Stoma site irritation			
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Stoma site pain			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Tooth fracture			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Cardiac disorders			
Palpitations			
subjects affected / exposed	1 / 9 (11.11%)	1 / 9 (11.11%)	0 / 11 (0.00%)
occurrences (all)	1	1	0
Sinus tachycardia			
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Nervous system disorders			
Ageusia			
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Amnesia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Aphasia			

subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Dizziness			
subjects affected / exposed	1 / 9 (11.11%)	1 / 9 (11.11%)	3 / 11 (27.27%)
occurrences (all)	1	1	3
Dysaesthesia			
subjects affected / exposed	2 / 9 (22.22%)	0 / 9 (0.00%)	1 / 11 (9.09%)
occurrences (all)	2	0	1
Dysgeusia			
subjects affected / exposed	3 / 9 (33.33%)	1 / 9 (11.11%)	0 / 11 (0.00%)
occurrences (all)	3	2	0
Head titubation			
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Headache			
subjects affected / exposed	1 / 9 (11.11%)	1 / 9 (11.11%)	4 / 11 (36.36%)
occurrences (all)	1	1	4
Hemiparesis			
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Hypoaesthesia			
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Hypogeusia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Memory impairment			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Migraine			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Neuropathy peripheral			
subjects affected / exposed	7 / 9 (77.78%)	3 / 9 (33.33%)	5 / 11 (45.45%)
occurrences (all)	8	4	5
Peripheral sensory neuropathy			

subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	5 / 11 (45.45%)
occurrences (all)	0	1	5
Restless legs syndrome			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Taste disorder			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Tremor			
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	2 / 9 (22.22%)	5 / 9 (55.56%)	4 / 11 (36.36%)
occurrences (all)	2	6	5
Increased tendency to bruise			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Leukocytosis			
subjects affected / exposed	1 / 9 (11.11%)	3 / 9 (33.33%)	0 / 11 (0.00%)
occurrences (all)	1	3	0
Leukopenia			
subjects affected / exposed	1 / 9 (11.11%)	1 / 9 (11.11%)	3 / 11 (27.27%)
occurrences (all)	2	3	3
Lymph node pain			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Lymphadenopathy			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Lymphopenia			
subjects affected / exposed	0 / 9 (0.00%)	2 / 9 (22.22%)	1 / 11 (9.09%)
occurrences (all)	0	3	1
Neutropenia			
subjects affected / exposed	2 / 9 (22.22%)	5 / 9 (55.56%)	5 / 11 (45.45%)
occurrences (all)	7	13	5



Thrombocytopenia subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	7 / 9 (77.78%) 16	0 / 11 (0.00%) 0
Ear and labyrinth disorders			
Ear pain subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	1 / 11 (9.09%) 1
Vertigo subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0
Eye disorders			
Abnormal sensation in eye subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0
Blindness transient subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0
Cataract subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0
Diplopia subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0
Dry eye subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0
Eczema eyelids subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0
Eye inflammation subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0
Eye pain subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0
Lacrimation increased			

subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Periorbital oedema			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Photophobia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Vision blurred			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	3 / 11 (27.27%)
occurrences (all)	0	0	3
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 11 (0.00%)
occurrences (all)	0	16	0
Abdominal distension			
subjects affected / exposed	0 / 9 (0.00%)	2 / 9 (22.22%)	0 / 11 (0.00%)
occurrences (all)	0	2	0
Abdominal hernia			
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Abdominal pain			
subjects affected / exposed	1 / 9 (11.11%)	1 / 9 (11.11%)	2 / 11 (18.18%)
occurrences (all)	1	1	3
Abdominal pain lower			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Abdominal pain upper			
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	2	0	0
Anal fissure			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Anal incontinence			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0

Anorectal swelling			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Aphthous ulcer			
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Ascites			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Cheilitis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Constipation			
subjects affected / exposed	3 / 9 (33.33%)	1 / 9 (11.11%)	3 / 11 (27.27%)
occurrences (all)	3	2	4
Defaecation urgency			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Dental caries			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Diarrhoea			
subjects affected / exposed	3 / 9 (33.33%)	5 / 9 (55.56%)	6 / 11 (54.55%)
occurrences (all)	6	6	6
Dyspepsia			
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Dysphagia			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Epigastric discomfort			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Eructation			
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0

Faeces soft			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Flatulence			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Frequent bowel movements			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Gastritis			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	1 / 11 (9.09%)
occurrences (all)	0	1	1
Gingival bleeding			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Haematochezia			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Haemorrhoids			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Hypoaesthesia oral			
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Hypoaesthesia teeth			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Mouth ulceration			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	2 / 9 (22.22%)	5 / 9 (55.56%)	8 / 11 (72.73%)
occurrences (all)	3	5	13

Oesophageal spasm subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0
Oesophagitis subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	1 / 11 (9.09%) 1
Salivary hypersecretion subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0
Stomatitis subjects affected / exposed occurrences (all)	3 / 9 (33.33%) 3	3 / 9 (33.33%) 4	2 / 11 (18.18%) 2
Toothache subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 9 (11.11%) 1	0 / 11 (0.00%) 0
Vomiting subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	3 / 9 (33.33%) 3	5 / 11 (45.45%) 5
Skin and subcutaneous tissue disorders			
Alopecia subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	2 / 9 (22.22%) 2	5 / 11 (45.45%) 5
Blister subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0
Decubitus ulcer subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0
Dermatitis bullous subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0
Dermatitis contact subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 9 (11.11%) 1	0 / 11 (0.00%) 0
Dermatitis exfoliative			

subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Dermatitis psoriasiform			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Dry skin			
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	1 / 11 (9.09%)
occurrences (all)	1	0	1
Erythema			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Hyperhidrosis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Night sweats			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Palmar erythema			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Palmar-plantar erythrodysaesthesia syndrome			
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Petechiae			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	1 / 9 (11.11%)	1 / 9 (11.11%)	1 / 11 (9.09%)
occurrences (all)	1	1	1
Rash			
subjects affected / exposed	1 / 9 (11.11%)	4 / 9 (44.44%)	3 / 11 (27.27%)
occurrences (all)	2	5	3
Rash erythematous			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1

Rash maculo-papular subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0
Rash pruritic subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0
Skin exfoliation subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0
Renal and urinary disorders			
Haematuria subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	1 / 11 (9.09%) 1
Hydronephrosis subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0
Pollakiuria subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0
Renal salt-wasting syndrome subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	1 / 11 (9.09%) 1
Stress urinary incontinence subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0
Urinary incontinence subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	1 / 11 (9.09%) 1
Endocrine disorders			
Adrenal insufficiency subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	2 / 11 (18.18%) 2
Autoimmune thyroiditis subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0
Hyperthyroidism			

subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Hypothyroidism			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Steroid withdrawal syndrome			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Thyroiditis			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	3 / 11 (27.27%)
occurrences (all)	1	0	3
Back pain			
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	3 / 11 (27.27%)
occurrences (all)	1	0	3
Bone pain			
subjects affected / exposed	1 / 9 (11.11%)	3 / 9 (33.33%)	4 / 11 (36.36%)
occurrences (all)	1	3	5
Chest wall mass			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Flank pain			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Muscle spasms			
subjects affected / exposed	2 / 9 (22.22%)	1 / 9 (11.11%)	1 / 11 (9.09%)
occurrences (all)	2	1	1
Muscle tightness			
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Muscular weakness			



subjects affected / exposed	1 / 9 (11.11%)	1 / 9 (11.11%)	1 / 11 (9.09%)
occurrences (all)	1	1	1
Musculoskeletal chest pain			
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	1 / 11 (9.09%)
occurrences (all)	1	0	1
Musculoskeletal pain			
subjects affected / exposed	1 / 9 (11.11%)	1 / 9 (11.11%)	0 / 11 (0.00%)
occurrences (all)	1	1	0
Myalgia			
subjects affected / exposed	0 / 9 (0.00%)	2 / 9 (22.22%)	2 / 11 (18.18%)
occurrences (all)	0	2	2
Neck pain			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Osteoarthritis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Pain in extremity			
subjects affected / exposed	0 / 9 (0.00%)	2 / 9 (22.22%)	1 / 11 (9.09%)
occurrences (all)	0	2	1
Pain in jaw			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Infections and infestations			
Bacteroides bacteraemia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Body tinea			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Bronchitis			
subjects affected / exposed	0 / 9 (0.00%)	3 / 9 (33.33%)	1 / 11 (9.09%)
occurrences (all)	0	3	1
Candida infection			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0

Cellulitis			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Clostridium bacteraemia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Clostridium difficile colitis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Ear infection			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Escherichia infection			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Folliculitis			
subjects affected / exposed	0 / 9 (0.00%)	2 / 9 (22.22%)	2 / 11 (18.18%)
occurrences (all)	0	2	2
Fungal skin infection			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Gingivitis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Herpes virus infection			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Herpes zoster			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Hordeolum			
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0

Nasopharyngitis			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Oral candidiasis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Pneumonia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Pyuria			
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Rash pustular			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	2 / 11 (18.18%)
occurrences (all)	0	0	2
Respiratory tract infection			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Sinusitis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Staphylococcal infection			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Stoma site infection			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Tinea cruris			
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	2 / 11 (18.18%)
occurrences (all)	0	0	2
Urinary tract infection			
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	1 / 11 (9.09%)
occurrences (all)	1	0	1

Vulvovaginitis subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 9 (11.11%) 1	0 / 11 (0.00%) 0
Metabolism and nutrition disorders			
Decreased appetite subjects affected / exposed occurrences (all)	2 / 9 (22.22%) 2	2 / 9 (22.22%) 2	3 / 11 (27.27%) 3
Dehydration subjects affected / exposed occurrences (all)	3 / 9 (33.33%) 3	2 / 9 (22.22%) 3	1 / 11 (9.09%) 2
Fluid retention subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 9 (11.11%) 1	0 / 11 (0.00%) 0
Hypercalcaemia subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	3 / 11 (27.27%) 3
Hyperglycaemia subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0
Hyperkalaemia subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 9 (11.11%) 1	1 / 11 (9.09%) 1
Hypertriglyceridaemia subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	1 / 11 (9.09%) 1
Hyperuricaemia subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	1 / 11 (9.09%) 2
Hypoalbuminaemia subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0	0 / 11 (0.00%) 0
Hypocalcaemia subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 9 (11.11%) 1	0 / 11 (0.00%) 0
Hypokalaemia			

subjects affected / exposed	1 / 9 (11.11%)	1 / 9 (11.11%)	2 / 11 (18.18%)
occurrences (all)	1	1	3
Hypomagnesaemia			
subjects affected / exposed	1 / 9 (11.11%)	1 / 9 (11.11%)	3 / 11 (27.27%)
occurrences (all)	1	1	8
Hyponatraemia			
subjects affected / exposed	1 / 9 (11.11%)	1 / 9 (11.11%)	1 / 11 (9.09%)
occurrences (all)	1	1	1
Hypophosphataemia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	2 / 11 (18.18%)
occurrences (all)	0	0	2
Hypovolaemia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Iron overload			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Lactic acidosis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Vitamin D deficiency			
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1

<b>Non-serious adverse events</b>	Group D: Epa + Pembrolizumab + Pemetrexed and Platinum Agent	Group E: Epa + Pembrolizumab + Cyclophosphamide	Group F: Epa + Pembrolizumab + Gemcitabine and Platinum Agent
Total subjects affected by non-serious adverse events			
subjects affected / exposed	9 / 9 (100.00%)	13 / 13 (100.00%)	8 / 8 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Neoplasm progression			
subjects affected / exposed	1 / 9 (11.11%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Tumour flare			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Tumour haemorrhage			

subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Tumour inflammation			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Tumour pain			
subjects affected / exposed	2 / 9 (22.22%)	1 / 13 (7.69%)	1 / 8 (12.50%)
occurrences (all)	2	1	1
Vascular disorders			
Capillary leak syndrome			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Flushing			
subjects affected / exposed	1 / 9 (11.11%)	1 / 13 (7.69%)	0 / 8 (0.00%)
occurrences (all)	1	1	0
Hot flush			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Hypertension			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Hypotension			
subjects affected / exposed	0 / 9 (0.00%)	1 / 13 (7.69%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Thrombophlebitis superficial			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Thrombosis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Vascular pain			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			

Asthenia			
subjects affected / exposed	1 / 9 (11.11%)	1 / 13 (7.69%)	1 / 8 (12.50%)
occurrences (all)	1	1	1
Axillary pain			
subjects affected / exposed	1 / 9 (11.11%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Catheter site pain			
subjects affected / exposed	0 / 9 (0.00%)	1 / 13 (7.69%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Chest discomfort			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Chills			
subjects affected / exposed	2 / 9 (22.22%)	3 / 13 (23.08%)	0 / 8 (0.00%)
occurrences (all)	2	4	0
Facial pain			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Fatigue			
subjects affected / exposed	7 / 9 (77.78%)	6 / 13 (46.15%)	4 / 8 (50.00%)
occurrences (all)	7	6	4
Gait disturbance			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Generalised oedema			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Influenza like illness			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Malaise			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Non-cardiac chest pain			
subjects affected / exposed	1 / 9 (11.11%)	2 / 13 (15.38%)	0 / 8 (0.00%)
occurrences (all)	1	3	0

Oedema			
subjects affected / exposed	0 / 9 (0.00%)	1 / 13 (7.69%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Oedema peripheral			
subjects affected / exposed	0 / 9 (0.00%)	1 / 13 (7.69%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Pain			
subjects affected / exposed	1 / 9 (11.11%)	1 / 13 (7.69%)	0 / 8 (0.00%)
occurrences (all)	1	2	0
Pyrexia			
subjects affected / exposed	1 / 9 (11.11%)	2 / 13 (15.38%)	0 / 8 (0.00%)
occurrences (all)	1	2	0
Temperature intolerance			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Immune system disorders			
Drug hypersensitivity			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Seasonal allergy			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			
Testicular pain			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Vaginal haemorrhage			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Vaginal ulceration			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	1 / 9 (11.11%)	1 / 13 (7.69%)	0 / 8 (0.00%)
occurrences (all)	1	1	0



Dysphonia			
subjects affected / exposed	1 / 9 (11.11%)	0 / 13 (0.00%)	1 / 8 (12.50%)
occurrences (all)	1	0	1
Dyspnoea			
subjects affected / exposed	1 / 9 (11.11%)	0 / 13 (0.00%)	3 / 8 (37.50%)
occurrences (all)	1	0	3
Dyspnoea exertional			
subjects affected / exposed	0 / 9 (0.00%)	1 / 13 (7.69%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Epistaxis			
subjects affected / exposed	2 / 9 (22.22%)	0 / 13 (0.00%)	1 / 8 (12.50%)
occurrences (all)	2	0	1
Haemoptysis			
subjects affected / exposed	1 / 9 (11.11%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Hiccups			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Hypoxia			
subjects affected / exposed	1 / 9 (11.11%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Nasal congestion			
subjects affected / exposed	0 / 9 (0.00%)	1 / 13 (7.69%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Nasal discomfort			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Painful respiration			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Pharyngeal inflammation			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0

Pneumonitis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Pneumothorax			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Productive cough			
subjects affected / exposed	2 / 9 (22.22%)	0 / 13 (0.00%)	1 / 8 (12.50%)
occurrences (all)	2	0	1
Pulmonary embolism			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Pulmonary fibrosis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Rhinitis allergic			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Wheezing			
subjects affected / exposed	1 / 9 (11.11%)	0 / 13 (0.00%)	1 / 8 (12.50%)
occurrences (all)	1	0	1
Psychiatric disorders			
Anxiety			
subjects affected / exposed	1 / 9 (11.11%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Depression			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	3 / 9 (33.33%)	2 / 13 (15.38%)	0 / 8 (0.00%)
occurrences (all)	3	2	0
Irritability			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Mental status changes			

subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 13 (0.00%) 0	0 / 8 (0.00%) 0
Product issues Stent malfunction subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 13 (0.00%) 0	0 / 8 (0.00%) 0
Investigations Activated partial thromboplastin time prolonged subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 13 (7.69%) 1	0 / 8 (0.00%) 0
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	3 / 9 (33.33%) 3	1 / 13 (7.69%) 1	2 / 8 (25.00%) 3
Amylase increased subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	1 / 13 (7.69%) 1	0 / 8 (0.00%) 0
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	3 / 9 (33.33%) 3	1 / 13 (7.69%) 1	1 / 8 (12.50%) 1
Blood alkaline phosphatase increased subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	2 / 13 (15.38%) 2	2 / 8 (25.00%) 2
Blood bilirubin increased subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 13 (0.00%) 0	0 / 8 (0.00%) 0
Blood creatinine increased subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 13 (0.00%) 0	1 / 8 (12.50%) 1
Blood lactate dehydrogenase increased subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 13 (7.69%) 2	0 / 8 (0.00%) 0
Blood pressure increased subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 13 (0.00%) 0	1 / 8 (12.50%) 1
Lipase increased			

subjects affected / exposed	1 / 9 (11.11%)	1 / 13 (7.69%)	0 / 8 (0.00%)
occurrences (all)	1	1	0
Lymphocyte count decreased			
subjects affected / exposed	1 / 9 (11.11%)	2 / 13 (15.38%)	0 / 8 (0.00%)
occurrences (all)	1	2	0
Neutrophil count decreased			
subjects affected / exposed	0 / 9 (0.00%)	1 / 13 (7.69%)	1 / 8 (12.50%)
occurrences (all)	0	2	1
Neutrophil toxic granulation present			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Platelet count decreased			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	2
Shift to the left			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Transaminases increased			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Weight decreased			
subjects affected / exposed	0 / 9 (0.00%)	2 / 13 (15.38%)	1 / 8 (12.50%)
occurrences (all)	0	2	1
Weight increased			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
White blood cell count decreased			
subjects affected / exposed	2 / 9 (22.22%)	1 / 13 (7.69%)	1 / 8 (12.50%)
occurrences (all)	2	3	1
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Incision site pain			

subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Infusion related reaction			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	2 / 8 (25.00%)
occurrences (all)	0	0	2
Skin abrasion			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Stoma site haemorrhage			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Stoma site inflammation			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Stoma site irritation			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Stoma site pain			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Tooth fracture			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Palpitations			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Sinus tachycardia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Ageusia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Amnesia			

subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Aphasia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Dizziness			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Dysaesthesia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Dysgeusia			
subjects affected / exposed	0 / 9 (0.00%)	1 / 13 (7.69%)	1 / 8 (12.50%)
occurrences (all)	0	1	1
Head titubation			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Headache			
subjects affected / exposed	1 / 9 (11.11%)	0 / 13 (0.00%)	2 / 8 (25.00%)
occurrences (all)	1	0	2
Hemiparesis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Hypoaesthesia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Hypogeusia			
subjects affected / exposed	0 / 9 (0.00%)	1 / 13 (7.69%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Memory impairment			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Migraine			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Neuropathy peripheral			

subjects affected / exposed	3 / 9 (33.33%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	3	0	0
Peripheral sensory neuropathy			
subjects affected / exposed	1 / 9 (11.11%)	0 / 13 (0.00%)	1 / 8 (12.50%)
occurrences (all)	1	0	1
Restless legs syndrome			
subjects affected / exposed	1 / 9 (11.11%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Taste disorder			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Tremor			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	3 / 9 (33.33%)	6 / 13 (46.15%)	4 / 8 (50.00%)
occurrences (all)	4	9	4
Increased tendency to bruise			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Leukocytosis			
subjects affected / exposed	1 / 9 (11.11%)	0 / 13 (0.00%)	2 / 8 (25.00%)
occurrences (all)	1	0	2
Leukopenia			
subjects affected / exposed	2 / 9 (22.22%)	1 / 13 (7.69%)	4 / 8 (50.00%)
occurrences (all)	2	1	8
Lymph node pain			
subjects affected / exposed	0 / 9 (0.00%)	1 / 13 (7.69%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Lymphadenopathy			
subjects affected / exposed	1 / 9 (11.11%)	0 / 13 (0.00%)	1 / 8 (12.50%)
occurrences (all)	1	0	1
Lymphopenia			
subjects affected / exposed	1 / 9 (11.11%)	4 / 13 (30.77%)	2 / 8 (25.00%)
occurrences (all)	1	4	2

Neutropenia			
subjects affected / exposed	2 / 9 (22.22%)	2 / 13 (15.38%)	5 / 8 (62.50%)
occurrences (all)	2	5	9
Thrombocytopenia			
subjects affected / exposed	1 / 9 (11.11%)	0 / 13 (0.00%)	4 / 8 (50.00%)
occurrences (all)	1	0	5
Ear and labyrinth disorders			
Ear pain			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Vertigo			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Eye disorders			
Abnormal sensation in eye			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Blindness transient			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Cataract			
subjects affected / exposed	0 / 9 (0.00%)	1 / 13 (7.69%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Diplopia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Dry eye			
subjects affected / exposed	3 / 9 (33.33%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	3	0	0
Eczema eyelids			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Eye inflammation			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Eye pain			



subjects affected / exposed	1 / 9 (11.11%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Lacrimation increased			
subjects affected / exposed	1 / 9 (11.11%)	1 / 13 (7.69%)	0 / 8 (0.00%)
occurrences (all)	1	1	0
Periorbital oedema			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Photophobia			
subjects affected / exposed	1 / 9 (11.11%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Vision blurred			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Abdominal distension			
subjects affected / exposed	0 / 9 (0.00%)	1 / 13 (7.69%)	1 / 8 (12.50%)
occurrences (all)	0	1	1
Abdominal hernia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Abdominal pain			
subjects affected / exposed	0 / 9 (0.00%)	1 / 13 (7.69%)	2 / 8 (25.00%)
occurrences (all)	0	1	2
Abdominal pain lower			
subjects affected / exposed	1 / 9 (11.11%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Abdominal pain upper			
subjects affected / exposed	0 / 9 (0.00%)	1 / 13 (7.69%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Anal fissure			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0

Anal incontinence			
subjects affected / exposed	0 / 9 (0.00%)	1 / 13 (7.69%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Anorectal swelling			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Aphthous ulcer			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Ascites			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Cheilitis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	3 / 9 (33.33%)	1 / 13 (7.69%)	2 / 8 (25.00%)
occurrences (all)	3	1	2
Defaecation urgency			
subjects affected / exposed	0 / 9 (0.00%)	1 / 13 (7.69%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Dental caries			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Diarrhoea			
subjects affected / exposed	4 / 9 (44.44%)	4 / 13 (30.77%)	0 / 8 (0.00%)
occurrences (all)	4	5	0
Dyspepsia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Dysphagia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Epigastric discomfort			
subjects affected / exposed	1 / 9 (11.11%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0

Eructation			
subjects affected / exposed	1 / 9 (11.11%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Faeces soft			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Flatulence			
subjects affected / exposed	0 / 9 (0.00%)	1 / 13 (7.69%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Frequent bowel movements			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Gastritis			
subjects affected / exposed	2 / 9 (22.22%)	0 / 13 (0.00%)	1 / 8 (12.50%)
occurrences (all)	2	0	1
Gastrooesophageal reflux disease			
subjects affected / exposed	1 / 9 (11.11%)	0 / 13 (0.00%)	1 / 8 (12.50%)
occurrences (all)	1	0	1
Gingival bleeding			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Haematochezia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Haemorrhoids			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Hypoaesthesia oral			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Hypoaesthesia teeth			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Mouth ulceration			
subjects affected / exposed	1 / 9 (11.11%)	0 / 13 (0.00%)	1 / 8 (12.50%)
occurrences (all)	1	0	1

Nausea			
subjects affected / exposed	7 / 9 (77.78%)	4 / 13 (30.77%)	4 / 8 (50.00%)
occurrences (all)	7	5	4
Oesophageal spasm			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Oesophagitis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Salivary hypersecretion			
subjects affected / exposed	1 / 9 (11.11%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Stomatitis			
subjects affected / exposed	2 / 9 (22.22%)	1 / 13 (7.69%)	0 / 8 (0.00%)
occurrences (all)	3	1	0
Toothache			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	3 / 9 (33.33%)	3 / 13 (23.08%)	3 / 8 (37.50%)
occurrences (all)	3	4	3
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	0 / 9 (0.00%)	1 / 13 (7.69%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Blister			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Decubitus ulcer			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Dermatitis bullous			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Dermatitis contact			

subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Dermatitis exfoliative			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Dermatitis psoriasiform			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	0 / 9 (0.00%)	1 / 13 (7.69%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Hyperhidrosis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Night sweats			
subjects affected / exposed	2 / 9 (22.22%)	1 / 13 (7.69%)	0 / 8 (0.00%)
occurrences (all)	2	1	0
Palmar erythema			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Palmar-plantar erythrodysesthesia syndrome			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Petechiae			
subjects affected / exposed	1 / 9 (11.11%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Pruritus			
subjects affected / exposed	3 / 9 (33.33%)	1 / 13 (7.69%)	2 / 8 (25.00%)
occurrences (all)	3	1	2
Rash			
subjects affected / exposed	0 / 9 (0.00%)	1 / 13 (7.69%)	2 / 8 (25.00%)
occurrences (all)	0	1	2

Rash erythematous subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 13 (0.00%) 0	0 / 8 (0.00%) 0
Rash maculo-papular subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	1 / 13 (7.69%) 1	0 / 8 (0.00%) 0
Rash pruritic subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	2 / 13 (15.38%) 2	0 / 8 (0.00%) 0
Skin exfoliation subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 13 (0.00%) 0	0 / 8 (0.00%) 0
Renal and urinary disorders			
Haematuria subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 13 (0.00%) 0	0 / 8 (0.00%) 0
Hydronephrosis subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 13 (0.00%) 0	0 / 8 (0.00%) 0
Pollakiuria subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 13 (0.00%) 0	0 / 8 (0.00%) 0
Renal salt-wasting syndrome subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 13 (0.00%) 0	0 / 8 (0.00%) 0
Stress urinary incontinence subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 13 (7.69%) 1	0 / 8 (0.00%) 0
Urinary incontinence subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 13 (0.00%) 0	0 / 8 (0.00%) 0
Endocrine disorders			
Adrenal insufficiency subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 13 (0.00%) 0	0 / 8 (0.00%) 0
Autoimmune thyroiditis			

subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Hyperthyroidism			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Hypothyroidism			
subjects affected / exposed	1 / 9 (11.11%)	0 / 13 (0.00%)	1 / 8 (12.50%)
occurrences (all)	1	0	1
Steroid withdrawal syndrome			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Thyroiditis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 9 (0.00%)	1 / 13 (7.69%)	1 / 8 (12.50%)
occurrences (all)	0	1	1
Back pain			
subjects affected / exposed	0 / 9 (0.00%)	1 / 13 (7.69%)	1 / 8 (12.50%)
occurrences (all)	0	1	1
Bone pain			
subjects affected / exposed	1 / 9 (11.11%)	0 / 13 (0.00%)	1 / 8 (12.50%)
occurrences (all)	1	0	1
Chest wall mass			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Flank pain			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Muscle spasms			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Muscle tightness			

subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Muscular weakness			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	2
Musculoskeletal pain			
subjects affected / exposed	0 / 9 (0.00%)	2 / 13 (15.38%)	0 / 8 (0.00%)
occurrences (all)	0	2	0
Myalgia			
subjects affected / exposed	1 / 9 (11.11%)	1 / 13 (7.69%)	1 / 8 (12.50%)
occurrences (all)	1	1	1
Neck pain			
subjects affected / exposed	0 / 9 (0.00%)	1 / 13 (7.69%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Osteoarthritis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Pain in jaw			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Bacteroides bacteraemia			
subjects affected / exposed	1 / 9 (11.11%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Body tinea			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Bronchitis			
subjects affected / exposed	2 / 9 (22.22%)	1 / 13 (7.69%)	0 / 8 (0.00%)
occurrences (all)	2	1	0



Candida infection			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Cellulitis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Clostridium bacteraemia			
subjects affected / exposed	1 / 9 (11.11%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Clostridium difficile colitis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			
subjects affected / exposed	1 / 9 (11.11%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Ear infection			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Escherichia infection			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Folliculitis			
subjects affected / exposed	1 / 9 (11.11%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Fungal skin infection			
subjects affected / exposed	0 / 9 (0.00%)	1 / 13 (7.69%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Gingivitis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Herpes virus infection			
subjects affected / exposed	0 / 9 (0.00%)	1 / 13 (7.69%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Herpes zoster			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0

Hordeolum			
subjects affected / exposed	1 / 9 (11.11%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Nasopharyngitis			
subjects affected / exposed	0 / 9 (0.00%)	1 / 13 (7.69%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Oral candidiasis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Pneumonia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Pyuria			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Rash pustular			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection			
subjects affected / exposed	0 / 9 (0.00%)	1 / 13 (7.69%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Sinusitis			
subjects affected / exposed	1 / 9 (11.11%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	3	0	0
Staphylococcal infection			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Stoma site infection			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Tinea cruris			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	1 / 9 (11.11%)	0 / 13 (0.00%)	2 / 8 (25.00%)
occurrences (all)	1	0	3

Urinary tract infection subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	2 / 13 (15.38%) 2	0 / 8 (0.00%) 0
Vulvovaginitis subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 13 (0.00%) 0	0 / 8 (0.00%) 0
Metabolism and nutrition disorders			
Decreased appetite subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 2	1 / 13 (7.69%) 1	0 / 8 (0.00%) 0
Dehydration subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	1 / 13 (7.69%) 1	1 / 8 (12.50%) 1
Fluid retention subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 13 (0.00%) 0	0 / 8 (0.00%) 0
Hypercalcaemia subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 13 (0.00%) 0	0 / 8 (0.00%) 0
Hyperglycaemia subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 13 (0.00%) 0	0 / 8 (0.00%) 0
Hyperkalaemia subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 13 (0.00%) 0	0 / 8 (0.00%) 0
Hypertriglyceridaemia subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 13 (0.00%) 0	0 / 8 (0.00%) 0
Hyperuricaemia subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 13 (0.00%) 0	0 / 8 (0.00%) 0
Hypoalbuminaemia subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	2 / 13 (15.38%) 2	0 / 8 (0.00%) 0
Hypocalcaemia			

subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Hypokalaemia			
subjects affected / exposed	3 / 9 (33.33%)	2 / 13 (15.38%)	0 / 8 (0.00%)
occurrences (all)	4	3	0
Hypomagnesaemia			
subjects affected / exposed	1 / 9 (11.11%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Hyponatraemia			
subjects affected / exposed	0 / 9 (0.00%)	1 / 13 (7.69%)	0 / 8 (0.00%)
occurrences (all)	0	2	0
Hypophosphataemia			
subjects affected / exposed	1 / 9 (11.11%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Hypovolaemia			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Iron overload			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Lactic acidosis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Vitamin D deficiency			
subjects affected / exposed	0 / 9 (0.00%)	0 / 13 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0

<b>Non-serious adverse events</b>	Group G: Epa + Pembrolizumab + 5-FU and Platinum Agent	Total	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	10 / 11 (90.91%)	68 / 70 (97.14%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Neoplasm progression			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Tumour flare			

subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Tumour haemorrhage			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Tumour inflammation			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Tumour pain			
subjects affected / exposed	2 / 11 (18.18%)	12 / 70 (17.14%)	
occurrences (all)	2	13	
Vascular disorders			
Capillary leak syndrome			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Flushing			
subjects affected / exposed	0 / 11 (0.00%)	3 / 70 (4.29%)	
occurrences (all)	0	4	
Hot flush			
subjects affected / exposed	0 / 11 (0.00%)	2 / 70 (2.86%)	
occurrences (all)	0	2	
Hypertension			
subjects affected / exposed	0 / 11 (0.00%)	2 / 70 (2.86%)	
occurrences (all)	0	2	
Hypotension			
subjects affected / exposed	0 / 11 (0.00%)	2 / 70 (2.86%)	
occurrences (all)	0	2	
Thrombophlebitis superficial			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Thrombosis			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Vascular pain			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	

General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 11 (0.00%)	7 / 70 (10.00%)	
occurrences (all)	0	7	
Axillary pain			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Catheter site pain			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Chest discomfort			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Chills			
subjects affected / exposed	0 / 11 (0.00%)	9 / 70 (12.86%)	
occurrences (all)	0	10	
Facial pain			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Fatigue			
subjects affected / exposed	4 / 11 (36.36%)	39 / 70 (55.71%)	
occurrences (all)	4	44	
Gait disturbance			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Generalised oedema			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Influenza like illness			
subjects affected / exposed	1 / 11 (9.09%)	3 / 70 (4.29%)	
occurrences (all)	1	3	
Malaise			
subjects affected / exposed	0 / 11 (0.00%)	2 / 70 (2.86%)	
occurrences (all)	0	3	
Non-cardiac chest pain			

subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	3 / 70 (4.29%) 4	
Oedema subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 70 (1.43%) 1	
Oedema peripheral subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	5 / 70 (7.14%) 5	
Pain subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	4 / 70 (5.71%) 5	
Pyrexia subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	6 / 70 (8.57%) 6	
Temperature intolerance subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 70 (1.43%) 1	
Immune system disorders Drug hypersensitivity subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 70 (1.43%) 1	
Seasonal allergy subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 70 (1.43%) 1	
Reproductive system and breast disorders Testicular pain subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 70 (1.43%) 1	
Vaginal haemorrhage subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	1 / 70 (1.43%) 1	
Vaginal ulceration subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 70 (1.43%) 1	
Respiratory, thoracic and mediastinal disorders			

Cough		
subjects affected / exposed	2 / 11 (18.18%)	10 / 70 (14.29%)
occurrences (all)	2	11
Dysphonia		
subjects affected / exposed	0 / 11 (0.00%)	2 / 70 (2.86%)
occurrences (all)	0	2
Dyspnoea		
subjects affected / exposed	0 / 11 (0.00%)	7 / 70 (10.00%)
occurrences (all)	0	8
Dyspnoea exertional		
subjects affected / exposed	0 / 11 (0.00%)	3 / 70 (4.29%)
occurrences (all)	0	3
Epistaxis		
subjects affected / exposed	0 / 11 (0.00%)	6 / 70 (8.57%)
occurrences (all)	0	6
Haemoptysis		
subjects affected / exposed	0 / 11 (0.00%)	2 / 70 (2.86%)
occurrences (all)	0	2
Hiccups		
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	1
Hypoxia		
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	1
Nasal congestion		
subjects affected / exposed	0 / 11 (0.00%)	3 / 70 (4.29%)
occurrences (all)	0	3
Nasal discomfort		
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	1
Oropharyngeal pain		
subjects affected / exposed	0 / 11 (0.00%)	2 / 70 (2.86%)
occurrences (all)	0	2
Painful respiration		
subjects affected / exposed	1 / 11 (9.09%)	1 / 70 (1.43%)
occurrences (all)	1	1



Pharyngeal inflammation			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Pneumonitis			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Pneumothorax			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Productive cough			
subjects affected / exposed	1 / 11 (9.09%)	5 / 70 (7.14%)	
occurrences (all)	1	6	
Pulmonary embolism			
subjects affected / exposed	0 / 11 (0.00%)	2 / 70 (2.86%)	
occurrences (all)	0	2	
Pulmonary fibrosis			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Rhinitis allergic			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Wheezing			
subjects affected / exposed	0 / 11 (0.00%)	3 / 70 (4.29%)	
occurrences (all)	0	3	
Psychiatric disorders			
Anxiety			
subjects affected / exposed	1 / 11 (9.09%)	2 / 70 (2.86%)	
occurrences (all)	1	2	
Depression			
subjects affected / exposed	1 / 11 (9.09%)	4 / 70 (5.71%)	
occurrences (all)	1	4	
Insomnia			
subjects affected / exposed	0 / 11 (0.00%)	10 / 70 (14.29%)	
occurrences (all)	0	10	
Irritability			

subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Mental status changes			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Product issues			
Stent malfunction			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Investigations			
Activated partial thromboplastin time prolonged			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Alanine aminotransferase increased			
subjects affected / exposed	1 / 11 (9.09%)	16 / 70 (22.86%)	
occurrences (all)	1	17	
Amylase increased			
subjects affected / exposed	0 / 11 (0.00%)	3 / 70 (4.29%)	
occurrences (all)	0	3	
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 11 (0.00%)	14 / 70 (20.00%)	
occurrences (all)	0	16	
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 11 (0.00%)	13 / 70 (18.57%)	
occurrences (all)	0	13	
Blood bilirubin increased			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Blood creatinine increased			
subjects affected / exposed	1 / 11 (9.09%)	6 / 70 (8.57%)	
occurrences (all)	1	8	
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	2	
Blood pressure increased			

subjects affected / exposed	0 / 11 (0.00%)	4 / 70 (5.71%)	
occurrences (all)	0	4	
Lipase increased			
subjects affected / exposed	1 / 11 (9.09%)	7 / 70 (10.00%)	
occurrences (all)	1	7	
Lymphocyte count decreased			
subjects affected / exposed	0 / 11 (0.00%)	5 / 70 (7.14%)	
occurrences (all)	0	5	
Neutrophil count decreased			
subjects affected / exposed	1 / 11 (9.09%)	8 / 70 (11.43%)	
occurrences (all)	1	13	
Neutrophil toxic granulation present			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Platelet count decreased			
subjects affected / exposed	0 / 11 (0.00%)	5 / 70 (7.14%)	
occurrences (all)	0	9	
Shift to the left			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Transaminases increased			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Weight decreased			
subjects affected / exposed	0 / 11 (0.00%)	6 / 70 (8.57%)	
occurrences (all)	0	6	
Weight increased			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
White blood cell count decreased			
subjects affected / exposed	0 / 11 (0.00%)	9 / 70 (12.86%)	
occurrences (all)	0	16	
Injury, poisoning and procedural complications			
Contusion			

subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Incision site pain			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Infusion related reaction			
subjects affected / exposed	0 / 11 (0.00%)	3 / 70 (4.29%)	
occurrences (all)	0	3	
Skin abrasion			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Stoma site haemorrhage			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Stoma site inflammation			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Stoma site irritation			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Stoma site pain			
subjects affected / exposed	0 / 11 (0.00%)	2 / 70 (2.86%)	
occurrences (all)	0	2	
Tooth fracture			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Cardiac disorders			
Palpitations			
subjects affected / exposed	1 / 11 (9.09%)	3 / 70 (4.29%)	
occurrences (all)	1	3	
Sinus tachycardia			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Nervous system disorders			
Ageusia			

subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	1
Amnesia		
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	1
Aphasia		
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	1
Dizziness		
subjects affected / exposed	2 / 11 (18.18%)	7 / 70 (10.00%)
occurrences (all)	2	7
Dysaesthesia		
subjects affected / exposed	0 / 11 (0.00%)	3 / 70 (4.29%)
occurrences (all)	0	3
Dysgeusia		
subjects affected / exposed	2 / 11 (18.18%)	8 / 70 (11.43%)
occurrences (all)	2	9
Head titubation		
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	1
Headache		
subjects affected / exposed	0 / 11 (0.00%)	9 / 70 (12.86%)
occurrences (all)	0	9
Hemiparesis		
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	1
Hypoaesthesia		
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	1
Hypogeusia		
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	1
Memory impairment		
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	1
Migraine		

subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Neuropathy peripheral			
subjects affected / exposed	1 / 11 (9.09%)	19 / 70 (27.14%)	
occurrences (all)	1	21	
Peripheral sensory neuropathy			
subjects affected / exposed	0 / 11 (0.00%)	8 / 70 (11.43%)	
occurrences (all)	0	8	
Restless legs syndrome			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Taste disorder			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Tremor			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	3 / 11 (27.27%)	27 / 70 (38.57%)	
occurrences (all)	3	33	
Increased tendency to bruise			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Leukocytosis			
subjects affected / exposed	1 / 11 (9.09%)	8 / 70 (11.43%)	
occurrences (all)	1	8	
Leukopenia			
subjects affected / exposed	1 / 11 (9.09%)	13 / 70 (18.57%)	
occurrences (all)	1	20	
Lymph node pain			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Lymphadenopathy			
subjects affected / exposed	0 / 11 (0.00%)	3 / 70 (4.29%)	
occurrences (all)	0	3	

Lymphopenia subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	11 / 70 (15.71%) 12	
Neutropenia subjects affected / exposed occurrences (all)	3 / 11 (27.27%) 3	24 / 70 (34.29%) 44	
Thrombocytopenia subjects affected / exposed occurrences (all)	2 / 11 (18.18%) 3	15 / 70 (21.43%) 26	
Ear and labyrinth disorders Ear pain subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 70 (1.43%) 1	
Vertigo subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 70 (1.43%) 1	
Eye disorders Abnormal sensation in eye subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 70 (1.43%) 1	
Blindness transient subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 70 (1.43%) 1	
Cataract subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 70 (1.43%) 1	
Diplopia subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 70 (1.43%) 1	
Dry eye subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	3 / 70 (4.29%) 3	
Eczema eyelids subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 70 (1.43%) 1	
Eye inflammation			

subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Eye pain			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Lacrimation increased			
subjects affected / exposed	0 / 11 (0.00%)	3 / 70 (4.29%)	
occurrences (all)	0	3	
Periorbital oedema			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Photophobia			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Vision blurred			
subjects affected / exposed	0 / 11 (0.00%)	3 / 70 (4.29%)	
occurrences (all)	0	3	
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	16	
Abdominal distension			
subjects affected / exposed	0 / 11 (0.00%)	4 / 70 (5.71%)	
occurrences (all)	0	4	
Abdominal hernia			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Abdominal pain			
subjects affected / exposed	1 / 11 (9.09%)	8 / 70 (11.43%)	
occurrences (all)	1	9	
Abdominal pain lower			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Abdominal pain upper			
subjects affected / exposed	1 / 11 (9.09%)	3 / 70 (4.29%)	
occurrences (all)	1	4	



Anal fissure		
subjects affected / exposed	1 / 11 (9.09%)	1 / 70 (1.43%)
occurrences (all)	1	1
Anal incontinence		
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	1
Anorectal swelling		
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	1
Aphthous ulcer		
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	1
Ascites		
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	1
Cheilitis		
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	1
Constipation		
subjects affected / exposed	0 / 11 (0.00%)	13 / 70 (18.57%)
occurrences (all)	0	15
Defaecation urgency		
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	1
Dental caries		
subjects affected / exposed	1 / 11 (9.09%)	1 / 70 (1.43%)
occurrences (all)	1	1
Diarrhoea		
subjects affected / exposed	4 / 11 (36.36%)	26 / 70 (37.14%)
occurrences (all)	5	32
Dyspepsia		
subjects affected / exposed	1 / 11 (9.09%)	2 / 70 (2.86%)
occurrences (all)	1	2
Dysphagia		
subjects affected / exposed	3 / 11 (27.27%)	5 / 70 (7.14%)
occurrences (all)	5	7

Epigastric discomfort		
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	1
Eructation		
subjects affected / exposed	0 / 11 (0.00%)	2 / 70 (2.86%)
occurrences (all)	0	2
Faeces soft		
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	1
Flatulence		
subjects affected / exposed	0 / 11 (0.00%)	2 / 70 (2.86%)
occurrences (all)	0	2
Frequent bowel movements		
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	1
Gastritis		
subjects affected / exposed	1 / 11 (9.09%)	5 / 70 (7.14%)
occurrences (all)	1	5
Gastrooesophageal reflux disease		
subjects affected / exposed	0 / 11 (0.00%)	4 / 70 (5.71%)
occurrences (all)	0	4
Gingival bleeding		
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	1
Haematochezia		
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	1
Haemorrhoids		
subjects affected / exposed	0 / 11 (0.00%)	2 / 70 (2.86%)
occurrences (all)	0	2
Hypoaesthesia oral		
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	1
Hypoaesthesia teeth		
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	1

Mouth ulceration			
subjects affected / exposed	1 / 11 (9.09%)	3 / 70 (4.29%)	
occurrences (all)	1	3	
Nausea			
subjects affected / exposed	7 / 11 (63.64%)	37 / 70 (52.86%)	
occurrences (all)	7	44	
Oesophageal spasm			
subjects affected / exposed	1 / 11 (9.09%)	1 / 70 (1.43%)	
occurrences (all)	1	1	
Oesophagitis			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Salivary hypersecretion			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Stomatitis			
subjects affected / exposed	5 / 11 (45.45%)	16 / 70 (22.86%)	
occurrences (all)	7	20	
Toothache			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Vomiting			
subjects affected / exposed	3 / 11 (27.27%)	20 / 70 (28.57%)	
occurrences (all)	3	21	
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	0 / 11 (0.00%)	9 / 70 (12.86%)	
occurrences (all)	0	9	
Blister			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Decubitus ulcer			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Dermatitis bullous			

subjects affected / exposed	1 / 11 (9.09%)	1 / 70 (1.43%)
occurrences (all)	1	1
Dermatitis contact		
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	1
Dermatitis exfoliative		
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	1
Dermatitis psoriasiform		
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	1
Dry skin		
subjects affected / exposed	0 / 11 (0.00%)	2 / 70 (2.86%)
occurrences (all)	0	2
Erythema		
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	1
Hyperhidrosis		
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	1
Night sweats		
subjects affected / exposed	1 / 11 (9.09%)	4 / 70 (5.71%)
occurrences (all)	1	4
Palmar erythema		
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	1
Palmar-plantar erythrodysesthesia syndrome		
subjects affected / exposed	1 / 11 (9.09%)	2 / 70 (2.86%)
occurrences (all)	1	2
Petechiae		
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	1
Pruritus		
subjects affected / exposed	1 / 11 (9.09%)	10 / 70 (14.29%)
occurrences (all)	2	11

Rash			
subjects affected / exposed	3 / 11 (27.27%)	14 / 70 (20.00%)	
occurrences (all)	4	17	
Rash erythematous			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Rash maculo-papular			
subjects affected / exposed	0 / 11 (0.00%)	3 / 70 (4.29%)	
occurrences (all)	0	3	
Rash pruritic			
subjects affected / exposed	1 / 11 (9.09%)	3 / 70 (4.29%)	
occurrences (all)	1	3	
Skin exfoliation			
subjects affected / exposed	1 / 11 (9.09%)	1 / 70 (1.43%)	
occurrences (all)	1	1	
Renal and urinary disorders			
Haematuria			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Hydronephrosis			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Pollakiuria			
subjects affected / exposed	1 / 11 (9.09%)	3 / 70 (4.29%)	
occurrences (all)	1	3	
Renal salt-wasting syndrome			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Stress urinary incontinence			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Urinary incontinence			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Endocrine disorders			

Adrenal insufficiency			
subjects affected / exposed	0 / 11 (0.00%)	2 / 70 (2.86%)	
occurrences (all)	0	2	
Autoimmune thyroiditis			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Hyperthyroidism			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Hypothyroidism			
subjects affected / exposed	0 / 11 (0.00%)	2 / 70 (2.86%)	
occurrences (all)	0	2	
Steroid withdrawal syndrome			
subjects affected / exposed	1 / 11 (9.09%)	1 / 70 (1.43%)	
occurrences (all)	1	1	
Thyroiditis			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 11 (9.09%)	7 / 70 (10.00%)	
occurrences (all)	2	8	
Back pain			
subjects affected / exposed	0 / 11 (0.00%)	6 / 70 (8.57%)	
occurrences (all)	0	6	
Bone pain			
subjects affected / exposed	0 / 11 (0.00%)	10 / 70 (14.29%)	
occurrences (all)	0	11	
Chest wall mass			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Flank pain			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Muscle spasms			

subjects affected / exposed	0 / 11 (0.00%)	4 / 70 (5.71%)	
occurrences (all)	0	4	
Muscle tightness			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Muscular weakness			
subjects affected / exposed	0 / 11 (0.00%)	3 / 70 (4.29%)	
occurrences (all)	0	3	
Musculoskeletal chest pain			
subjects affected / exposed	1 / 11 (9.09%)	4 / 70 (5.71%)	
occurrences (all)	1	5	
Musculoskeletal pain			
subjects affected / exposed	0 / 11 (0.00%)	4 / 70 (5.71%)	
occurrences (all)	0	4	
Myalgia			
subjects affected / exposed	0 / 11 (0.00%)	7 / 70 (10.00%)	
occurrences (all)	0	7	
Neck pain			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Osteoarthritis			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Pain in extremity			
subjects affected / exposed	0 / 11 (0.00%)	3 / 70 (4.29%)	
occurrences (all)	0	3	
Pain in jaw			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Infections and infestations			
Bacteroides bacteraemia			
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)	
occurrences (all)	0	1	
Body tinea			
subjects affected / exposed	1 / 11 (9.09%)	1 / 70 (1.43%)	
occurrences (all)	1	1	

Bronchitis		
subjects affected / exposed	0 / 11 (0.00%)	7 / 70 (10.00%)
occurrences (all)	0	7
Candida infection		
subjects affected / exposed	1 / 11 (9.09%)	1 / 70 (1.43%)
occurrences (all)	1	1
Cellulitis		
subjects affected / exposed	2 / 11 (18.18%)	3 / 70 (4.29%)
occurrences (all)	2	3
Clostridium bacteraemia		
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	1
Clostridium difficile colitis		
subjects affected / exposed	1 / 11 (9.09%)	1 / 70 (1.43%)
occurrences (all)	1	1
Conjunctivitis		
subjects affected / exposed	0 / 11 (0.00%)	2 / 70 (2.86%)
occurrences (all)	0	2
Ear infection		
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	1
Escherichia infection		
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	1
Folliculitis		
subjects affected / exposed	0 / 11 (0.00%)	5 / 70 (7.14%)
occurrences (all)	0	5
Fungal skin infection		
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	1
Gingivitis		
subjects affected / exposed	1 / 11 (9.09%)	1 / 70 (1.43%)
occurrences (all)	1	1
Herpes virus infection		
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	1



Herpes zoster		
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	1
Hordeolum		
subjects affected / exposed	0 / 11 (0.00%)	2 / 70 (2.86%)
occurrences (all)	0	2
Nasopharyngitis		
subjects affected / exposed	0 / 11 (0.00%)	2 / 70 (2.86%)
occurrences (all)	0	2
Oral candidiasis		
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	1
Pneumonia		
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	1
Pyuria		
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	1
Rash pustular		
subjects affected / exposed	0 / 11 (0.00%)	2 / 70 (2.86%)
occurrences (all)	0	2
Respiratory tract infection		
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	1
Sinusitis		
subjects affected / exposed	1 / 11 (9.09%)	2 / 70 (2.86%)
occurrences (all)	1	4
Staphylococcal infection		
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	1
Stoma site infection		
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	1
Tinea cruris		
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	1

Upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	5 / 70 (7.14%) 6	
Urinary tract infection subjects affected / exposed occurrences (all)	2 / 11 (18.18%) 2	6 / 70 (8.57%) 6	
Vulvovaginitis subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 70 (1.43%) 1	
Metabolism and nutrition disorders			
Decreased appetite subjects affected / exposed occurrences (all)	3 / 11 (27.27%) 3	12 / 70 (17.14%) 13	
Dehydration subjects affected / exposed occurrences (all)	4 / 11 (36.36%) 4	13 / 70 (18.57%) 15	
Fluid retention subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 70 (1.43%) 1	
Hypercalcaemia subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	3 / 70 (4.29%) 3	
Hyperglycaemia subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 70 (1.43%) 1	
Hyperkalaemia subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	3 / 70 (4.29%) 3	
Hypertriglyceridaemia subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 70 (1.43%) 1	
Hyperuricaemia subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 70 (1.43%) 2	
Hypoalbuminaemia			

subjects affected / exposed	0 / 11 (0.00%)	3 / 70 (4.29%)
occurrences (all)	0	3
Hypocalcaemia		
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	1
Hypokalaemia		
subjects affected / exposed	1 / 11 (9.09%)	10 / 70 (14.29%)
occurrences (all)	1	13
Hypomagnesaemia		
subjects affected / exposed	1 / 11 (9.09%)	7 / 70 (10.00%)
occurrences (all)	1	12
Hyponatraemia		
subjects affected / exposed	0 / 11 (0.00%)	4 / 70 (5.71%)
occurrences (all)	0	5
Hypophosphataemia		
subjects affected / exposed	0 / 11 (0.00%)	3 / 70 (4.29%)
occurrences (all)	0	3
Hypovolaemia		
subjects affected / exposed	1 / 11 (9.09%)	1 / 70 (1.43%)
occurrences (all)	1	1
Iron overload		
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	1
Lactic acidosis		
subjects affected / exposed	1 / 11 (9.09%)	1 / 70 (1.43%)
occurrences (all)	1	1
Vitamin D deficiency		
subjects affected / exposed	0 / 11 (0.00%)	1 / 70 (1.43%)
occurrences (all)	0	1

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
10 January 2017	The primary purpose of amendment #1 was to address FDA's correspondence from 03 JAN 2017.
28 March 2017	The primary purpose of amendment #2 was to update the study design of both Phase 1 and Phase 2 and provide clarity within the Protocol with respect to definition of study drug.
18 May 2017	The primary purpose of amendment #3 was to update the study design of Phase 1 and provide flexibility in DLT determination in Phase 1.
31 July 2017	The primary purpose of amendment #4 was to update the study design.
02 February 2018	The primary purpose of amendment #5 is to update the dose modification guidance for epacadostat and pembrolizumab for the management of immune-related adverse events.
31 August 2018	The primary purpose of amendment #6 was to update the study design based on recent developments in the epacadostat clinical development program.
14 February 2019	The primary purpose of amendment #7 was to provide guidance for the management of ongoing subjects as enrollment has been terminated for the study as of 25 OCT 2018.

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Enrollment in this study was permanently discontinued on 25 Oct 2018 due to a strategic decision and not based on safety concerns.

Notes: